Back to search results

Exercise and Brain Stimulation for Breast Cancer Survivors

This study is looking at a new way to help breast cancer survivors who have trouble with memory and thinking after treatment. It combines exercise with transcranial alternating current stimulation (tACS), which is a gentle way to stimulate the brain. You might be able to join if you are a breast cancer survivor (stages 0-3), are at least 18 years old, finished your main cancer treatments at least three months ago, and feel like your thinking skills have been affected. The study wants to see if this combination of exercise and tACS is practical and helpful. Researchers will check if people stick with the program, like it, and if it's safe. They will also look at whether it improves attention, memory, and physical function. The study plans to enroll 40 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 40 participants. It compares an exercise and tACS group to a control group receiving exercise and a sham (inactive) tACS.
What's involved
Participants will complete a four-week program, attending three times a week. Each session involves 30 minutes of aerobic exercise, followed by 15 minutes of either tACS or sham tACS while doing a computer task, and a questionnaire.
Compensation
Not stated in the trial record.
Follow-up
Researchers will assess changes immediately after the 4-week intervention and again four weeks after the intervention ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07587957

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

Recruiting
NAAges 18+InterventionalSupportive care
Florida Atlantic University
~40 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:Exercise + transcranial alternating current stimulation (Ex+tACS)Control

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence
Measured over From baseline to the end of the 4-week intervention
+3 more outcomes measured

Conditions

Breast Cancer

Explore related trials

Breast CarcinomaCancer-related cognitive impairment

Where it's being run

1 sites across 1 states
Florida1

Who to contact

Ashley L Artese, PhD
[email protected]
856-534-8926
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed non-metastatic breast cancer (stages 0-3)
Completed primary breast cancer treatment (surgery, chemotherapy, radiation) for at least 3 months
Self-reported cognitive impairment after cancer treatment

Exclusion

Current participation in aerobic exercise for ≥60 min/wk
Contraindication or impairment that precludes the potential participant from exercise as defined by the American College of Sports Medicine
The presence of serious medical illnesses, metal implants, previous brain trauma, epilepsy or history of seizures, previous surgery to the head or spinal cord, or skin problems at the forehead area where the tACS electrodes will be applied
Uncontrolled cardiovascular disease
Functional impairments or physical condition that would make exercise unsafe
Metastatic cancer or diagnosis of a different cancer (excluding melanoma) within the past 5 years
Contraindication to exercise a defined by the American College of Sports Medicine

What this trial measures

  • AdherenceFrom baseline to the end of the 4-week intervention

    Adherence will be calculated based on the percentage of prescribed sessions attended and percentage of participants who complete the prescribed exercise and tACS sessions.

  • RetentionFrom baseline to the end of the 4-week intervention

    Retention will be determined by the number of enrolled breast cancer survivors who participate in the four-week intervention and complete post assessments.

  • AcceptabilityFrom baseline to the end of the 4-week intervention

    Acceptability will be determined by the percentage of participants who report satisfaction with the intervention.

  • Safety (Adverse Events)From baseline to the end of the 4-week intervention

    Safety (\<5% of serious adverse events) will be determined by the percentage of participants experiencing a serious adverse event related to the program.